Open forum infectious diseases · 2026
Clinical Characteristics and Management of Non-Tuberculous Mycobacterial Skin and Soft Tissue Infections: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peeters Wouter, van Lier Chang, van Ingen Jakko, van Houdt Claire, van Crevel Reinout, van Hees Colette, Bax Hannelore, van den Reek Juul, van Laarhoven Arjan
Аннотация
BACKGROUND: Non-tuberculous mycobacterial (NTM) skin and soft tissue infections (SSTI) present a significant treatment challenge, requiring prolonged, multidrug antibiotic regimens often associated with substantial toxicity and suboptimal clinical outcomes. We aim to describe the clinical characteristics and treatment of patients with NTM-SSTI in the Netherlands, focusing on host immune status and drug toxicity.
METHODS: We retrospectively collected data from adults with NTM-SSTI treated at 2 Dutch tertiary referral centers for mycobacterial disease between 2017 and 2024. Data included sociodemographics, medical history, antibiotic regimens, drug toxicity, and treatment outcomes.
RESULTS: We included 73 patients, of whom 39 (49%) were immunocompromised. Disseminated disease was almost exclusively observed in immunocompromised patients (14/15). The most isolated species were Mycobacterium chelonae (23/73; 32%) and Mycobacterium marinum (17/73; 23%). Azithromycin, the most prescribed drug, was discontinued prematurely because of toxicity in 35% (18/52) of patients, ethambutol in 33% (9/27), and clofazimine in only 12% (3/26). These discontinuations occurred mostly within the first 4 months. Immunocompromised patients with disseminated infections had longer (median 10.1 vs 7.6 vs 6.4 months) treatment durations and lower remission rates (29% vs 59% vs 86%) compared to immunocompromised patients with localized disease and immunocompetent patients, respectively.
CONCLUSIONS: Immunocompromised status is associated with disseminated NTM-SSTI and worse treatment outcomes. Regardless of immune status, antimycobacterial drugs often cause toxicity, leading to treatment changes.
METHODS: We retrospectively collected data from adults with NTM-SSTI treated at 2 Dutch tertiary referral centers for mycobacterial disease between 2017 and 2024. Data included sociodemographics, medical history, antibiotic regimens, drug toxicity, and treatment outcomes.
RESULTS: We included 73 patients, of whom 39 (49%) were immunocompromised. Disseminated disease was almost exclusively observed in immunocompromised patients (14/15). The most isolated species were Mycobacterium chelonae (23/73; 32%) and Mycobacterium marinum (17/73; 23%). Azithromycin, the most prescribed drug, was discontinued prematurely because of toxicity in 35% (18/52) of patients, ethambutol in 33% (9/27), and clofazimine in only 12% (3/26). These discontinuations occurred mostly within the first 4 months. Immunocompromised patients with disseminated infections had longer (median 10.1 vs 7.6 vs 6.4 months) treatment durations and lower remission rates (29% vs 59% vs 86%) compared to immunocompromised patients with localized disease and immunocompetent patients, respectively.
CONCLUSIONS: Immunocompromised status is associated with disseminated NTM-SSTI and worse treatment outcomes. Regardless of immune status, antimycobacterial drugs often cause toxicity, leading to treatment changes.